We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 21-40 of 96 results
  1. Utility of Technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer

    Background

    Technetium-99m methoxyisobutyl isonitrile (Tc-SESTAMIBI) is a substrate of P-glycoprotein and multidrug-resistance associated protein in...

    Ryungsa Kim, Akihiko Osaki, ... Tetsuya Toge in Breast Cancer
    Article 01 July 2002
  2. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)

    Expression of the multidrug resistance proteins P-glycoprotein, encoded by the MDR 1 gene, multidrug resistance-associated protein (MRP1) and the lung...

    MM van den Heuvel-Eibrink, EAC Wiemer, ... P Sonneveld in Leukemia
    Article 02 May 2002
  3. Biology and modulation of multidrug resistance (MDR) in hematological malignancies

    Drug resistance is one of the most significant impediments in the treatment of hematological malignancies. There have been a number of studies on the...

    Article 01 March 2002
  4. Rapid induction of long-lasting drug efflux activity in brain vascular endothelial cells but not malignant glioma following irradiation

    The influence of radiotherapy on malignant glioma multidrug resistance to chemotherapy was evaluated because patients with glioma often are treated...

    U. Andersson, K. Grankvist, ... R. Henriksson in Medical Oncology
    Article 01 March 2002
  5. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders

    The development of drugs to treat disorders of the CNS requires consideration of achievable brain concentrations. Factors that influence the brain...

    Eve M. Taylor in Clinical Pharmacokinetics
    Article 01 February 2002
  6. The Mucosa of the Small Intestine

    The intestinal mucosa is capable of metabolising drugs via phase I and II reactions. Increasingly, as a result of in vitro and in vivo (animal and...

    Margaret M. Doherty, William N. Charman in Clinical Pharmacokinetics
    Article 01 April 2002
  7. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1

    A spontaneously EBV transformed follicular lymphoma (FL) cell line, Tat-1, was established from the lymph node biopsy specimen of a patient with B...

    T Denyssevych, VS Lestou, ... LD Mayer in Leukemia
    Article 07 February 2002
  8. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut

    Background: Recent studies in mice and patients have shown that the low oral bioavailability of paclitaxel can be increased by coadministration of...

    Heleen A. Bardelmeijer, Mariët Ouwehand, ... Olaf van Tellingen in Cancer Chemotherapy and Pharmacology
    Article 20 November 2001
  9. Oral Delivery of Taxanes

    Oral treatment with cytotoxic agents is tobe preferred as this administration routeis convenient to patients, reducesadministration costs and...

    Mirte M. Malingré, Jos H. Beijnen, Jan H.M. Schellens in Investigational New Drugs
    Article 01 May 2001
  10. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats

    Purpose: 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17DMAG) is an analogue of the benzoquinone ansamycin compound...

    Merrill J. Egorin, Theodore F. Lagattuta, ... Julie L. Eiseman in Cancer Chemotherapy and Pharmacology
    Article 01 January 2002
  11. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents

    Background : The cyclosporins have been thought as being mainly immunosuppressive agents which interfere with the function of the MDR pump and thus...

    Willi Kreis, Daniel R. Budman, Anthony Calabro in Cancer Chemotherapy and Pharmacology
    Article 07 November 2000
  12. Taxol-induced ceramide generation and apoptosis in human breast cancer cells

    Purpose: Taxol has emerged as a valuable antimitotic chemotherapeutic agent, particularly in advanced breast and ovarian cancers. Although much is...

    Anthony G. Charles, Tie-Yan Han, ... Myles C. Cabot in Cancer Chemotherapy and Pharmacology
    Article 01 May 2001
  13. Overcoming drug resistance in ovarian carcinoma

    Advanced epithelial ovarian carcinoma is treated with cytoreductive surgery and combination chemotherapy with a platinum compound and paclitaxel....

    Paula M. Fracasso in Current Oncology Reports
    Article 01 February 2001
  14. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

    Purpose : To investigate dose escalation of bi-daily (b.i.d.) oral paclitaxel in combination with cyclosporin A in order to improve and prolong the...

    Mirte M. Malingré, Jos H. Beijnen, ... Jan H.M. Schellens in Cancer Chemotherapy and Pharmacology
    Article 16 February 2001
  15. Drug Interactions of Paclitaxel and Docetaxel and their Relevance for the Design of Combination Therapy

    The taxanes' interaction with otheranticancer drugs have been extensivelyinvestigated in in vitro and inanimal models as well as in humans due tothe...

    Lucia Vigano, Alberta Locatelli, ... Luca Gianni in Investigational New Drugs
    Article 01 May 2001
  16. Development of Multidrug-Resistance Convertors: Sense or Nonsense?

    This review describes the clinical relevance of the two drugtransporters P-glycoprotein (Pgp) and multidrugresistance-associated protein (MRP) and...

    Lia van Zuylen, Kees Nooter, ... Jaap Verweij in Investigational New Drugs
    Article 01 August 2000
  17. The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

    There is an increasing interest to administer cytotoxic drugs topatients by the oral route. Quality of life issues, treatmentadvantages and...

    Heleen A. Bardelmeijer, Olaf van Tellingen, ... Jos H. Beijnen in Investigational New Drugs
    Article 01 August 2000
  18. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1

    Purpose: 17-(Allylamino)-17-demethoxygeldanamycin (17AAG) is a benzoquinone ansamycin compound agent that has entered clinical trials. Studies were...

    Merrill J. Egorin, Eleanor G. Zuhowski, ... Julie L. Eiseman in Cancer Chemotherapy and Pharmacology
    Article 11 January 2001
  19. Constitutive and acquired resistance to calcineurin inhibitors in renal transplantation: role of P-glycoprotein-170

    The present study examines whether resistance to Cyclosporin A (CyA) and Tacrolimus (FK506) develops in T cells from individual patients and the...

    Michael P. Delaney, Emma Smythe, ... Alan G. Morris in Transplant International
    Article 01 July 2000
  20. Promising Approaches in Acute Leukemia

    In the last few decades, there has been a significant improvement in theprognosis of patients with acute leukemias. Still, the majority ofpatients...

    Jorge Cortes, Hagop M. Kantarjian in Investigational New Drugs
    Article 01 February 2000
Did you find what you were looking for? Share feedback.